MitoQ for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of California Los Angeles, Los Angeles, CA
COVID-19+3 More
Mitoquinone/mitoquinol mesylate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Open label clinical trial of persons (adults) that will determine the safety and efficacy of the diet supplement oral mitoquinone/mitoquinol mesylate (Mito-MES) to prevent the development and progression of severe viral infections like COVID-19 after high-risk exposure to a person with possible respiratory viral infection such as SARS-CoV-2 infection in persons who will receive Mito-MES compared to persons who will not receive Mito-MES (controls).

Eligible Conditions

  • COVID-19
  • Antiviral Treatment
  • Viral Respiratory Tract Infection

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for COVID-19

Study Objectives

6 Primary · 2 Secondary · Reporting Duration: 14 days

14 days
Development of symptoms of viral illness
Fever
Incidence of Treatment-Emergent Adverse Events as assessed by the proportion of participants exhibiting adverse events of any grade
Number of participants with any symptoms of viral illness
Number of participants with fever
Safety
Severity of viral illness
Severity score of symptoms of viral illness

Trial Safety

Safety Progress

1 of 3

Other trials for COVID-19

Trial Design

2 Treatment Groups

Control group
1 of 2
MitoQ
1 of 2
Active Control
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: MitoQ · No Placebo Group · Phase 1 & 2

MitoQ
Drug
Experimental Group · 1 Intervention: Mitoquinone/mitoquinol mesylate · Intervention Types: Drug
Control groupNoIntervention Group · 1 Intervention: Control group · Intervention Types:

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 14 days

Trial Background

Prof. Theodoros Kelesidis,, MD PhD
Principal Investigator
University of California, Los Angeles
Closest Location: University of California Los Angeles · Los Angeles, CA
Photo of university of california los angeles  1Photo of university of california los angeles  2Photo of university of california los angeles  3
2006First Recorded Clinical Trial
3 TrialsResearching COVID-19
130 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 18 and 65 years old.\n
You have no symptoms of a viral infection.
You have no documented history of kidney disease.
You have had at least two new onset independent symptoms or signs (fever) of respiratory viral disease.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.